NeurOp’s technology to optimize selective and context-dependent NMDA inhibitors has led to the discovery of several proprietary compounds. Screening for drug-like properties among this group of compounds led to the identification of NP10679.
- NP10679 is selective for a specific NMDA subtype, GluN2B, and has increased potency in acidic conditions.
- Over 100-fold more potent at GluN2B-containing NMDA receptors than other subtypes
- 6-fold greater potency in lower pH (acidic) environments, a context relevant to a number of CNS disorders
- Excellent drug-like properties, such as brain penetrance, half-life, oral bioavailability and weak CYP inhibition.
- Effective in animal models of stroke, subarachnoid hemorrhage (SAH), perioperative pain (preliminary data) and opiate relapse (preliminary data)
- Phase 1 clinical studies indicate excellent pharmacokinetics in humans
- Phase 1 studies also suggest good safety margins for a number of possible indications such as stroke, SAH and acute severe pain
Phase 1 studies of NP10679 have been completed, and we expect to begin Phase 2 studies in SAH in 2023.